Literature DB >> 21968427

The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Xiaozhe Wang1, David T Weaver.   

Abstract

PARP inhibitors are emerging as a valuable new drug class in the treatment of cancer. Recent discoveries make a compelling case for the complexity of DNA repair biomarker evaluation and underscore the need to examine at multiple biomarkers in a relational manner. This review updates the current trends in DNA repair biomarker strategies in use for the PARP inhibitors and describes the impact of many DNA repair biomarkers on PARP inhibitor benefit in the cancer clinic.

Entities:  

Year:  2010        PMID： 21968427      PMCID： PMC3180060     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN： 2156-6976            Impact factor:   6.166


  172 in total

Review 1.  Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair.

Authors:  Jennifer J Rahn; Gerald M Adair; Rodney S Nairn
Journal:  Environ Mol Mutagen       Date:  2010-07       Impact factor: 3.216

2.  Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

Authors:  Bing Xia; Josephine C Dorsman; Najim Ameziane; Yne de Vries; Martin A Rooimans; Qing Sheng; Gerard Pals; Abdellatif Errami; Eliane Gluckman; Julian Llera; Weidong Wang; David M Livingston; Hans Joenje; Johan P de Winter
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

3.  Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model.

Authors:  S B Wharton; U McNelis; H S Bell; I R Whittle
Journal:  Neuropathol Appl Neurobiol       Date:  2000-12       Impact factor: 8.090

4.  A recurrent mutation in PALB2 in Finnish cancer families.

Authors:  Hannele Erkko; Bing Xia; Jenni Nikkilä; Johanna Schleutker; Kirsi Syrjäkoski; Arto Mannermaa; Anne Kallioniemi; Katri Pylkäs; Sanna-Maria Karppinen; Katrin Rapakko; Alexander Miron; Qing Sheng; Guilan Li; Henna Mattila; Daphne W Bell; Daniel A Haber; Mervi Grip; Mervi Reiman; Arja Jukkola-Vuorinen; Aki Mustonen; Juha Kere; Lauri A Aaltonen; Veli-Matti Kosma; Vesa Kataja; Ylermi Soini; Ronny I Drapkin; David M Livingston; Robert Winqvist
Journal:  Nature       Date:  2007-02-07       Impact factor: 49.962

5.  Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.

Authors:  Niklas Schultz; Elena Lopez; Nasrollah Saleh-Gohari; Thomas Helleday
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

Review 6.  Molecular pathogenesis of Fanconi anemia: recent progress.

Authors:  Toshiyasu Taniguchi; Alan D D'Andrea
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

7.  Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins.

Authors:  Ivan Ahel; Dragana Ahel; Takahiro Matsusaka; Allison J Clark; Jonathon Pines; Simon J Boulton; Stephen C West
Journal:  Nature       Date:  2008-01-03       Impact factor: 49.962

Review 8.  Targeting the DNA damage response for cancer therapy.

Authors:  Simon N Powell; Ranjit S Bindra
Journal:  DNA Repair (Amst)       Date:  2009-06-05

9.  Molecular analysis-based treatment strategies for non-small cell lung cancer.

Authors:  Gerold Bepler; Mubeena Begum; George R Simon
Journal:  Cancer Control       Date:  2008-04       Impact factor: 3.302

10.  Analysis of PALB2/FANCN-associated breast cancer families.

Authors:  Marc Tischkowitz; Bing Xia; Nelly Sabbaghian; Jorge S Reis-Filho; Nancy Hamel; Guilan Li; Erik H van Beers; Lili Li; Tayma Khalil; Louise A Quenneville; Atilla Omeroglu; Aletta Poll; Pierre Lepage; Nora Wong; Petra M Nederlof; Alan Ashworth; Patricia N Tonin; Steven A Narod; David M Livingston; William D Foulkes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-09       Impact factor: 11.205
View more
  21 in total

Review 1.  The role of PARP1 in the DNA damage response and its application in tumor therapy.

Authors:  Zhifeng Wang; Fengli Wang; Tieshan Tang; Caixia Guo
Journal:  Front Med       Date:  2012-06-03       Impact factor: 4.592

2.  Targeting tumor suppressor networks for cancer therapeutics.

Authors:  Xuning Emily Guo; Bryan Ngo; Aram Sandaldjian Modrek; Wen-Hwa Lee
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

3.  Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.

Authors:  Melanie L Bailey; Nigel J O'Neil; Derek M van Pel; David A Solomon; Todd Waldman; Philip Hieter
Journal:  Mol Cancer Ther       Date:  2013-12-19       Impact factor: 6.261

4.  Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.

Authors:  Deanna M Janzen; Daniel Y Paik; Miguel A Rosales; Brian Yep; Donghui Cheng; Owen N Witte; Huseyin Kayadibi; Christopher M Ryan; Michael E Jung; Kym Faull; Sanaz Memarzadeh
Journal:  Mol Cancer Ther       Date:  2013-11-12       Impact factor: 6.261

5.  Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.

Authors:  Pawel Domagala; Anna Jakubowska; Katarzyna Jaworska-Bieniek; Katarzyna Kaczmarek; Katarzyna Durda; Agnieszka Kurlapska; Cezary Cybulski; Jan Lubinski
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

6.  Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.

Authors:  Neerav Shukla; Joshua Schiffman; Damon Reed; Ian J Davis; Richard B Womer; Stephen L Lessnick; Elizabeth R Lawlor
Journal:  Front Oncol       Date:  2013-06-06       Impact factor: 6.244

7.  Resistance to PARP-Inhibitors in Cancer Therapy.

Authors:  Alicia Montoni; Mihaela Robu; Emilie Pouliot; Girish M Shah
Journal:  Front Pharmacol       Date:  2013-02-27       Impact factor: 5.810

8.  Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage.

Authors:  Motokazu Ito; Shigeo Ohba; Karin Gaensler; Sabrina M Ronen; Joydeep Mukherjee; Russell O Pieper
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

9.  Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

Authors:  Anneleen Daemen; Denise M Wolf; James E Korkola; Obi L Griffith; Jessica R Frankum; Rachel Brough; Lakshmi R Jakkula; Nicholas J Wang; Rachael Natrajan; Jorge S Reis-Filho; Christopher J Lord; Alan Ashworth; Paul T Spellman; Joe W Gray; Laura J van't Veer
Journal:  Breast Cancer Res Treat       Date:  2012-08-09       Impact factor: 4.872

Review 10.  Profile of veliparib and its potential in the treatment of solid tumors.

Authors:  Lars M Wagner
Journal:  Onco Targets Ther       Date:  2015-07-29       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.